

Highly enantioselective Michael addition of ketones to nitroolefins catalyzed by (*S*)-pyrrolidine arenesulfonamide

Bukuo Ni, Qianying Zhang and Allan D. Headley*

Department of Chemistry, Texas A&M University-Commerce, Commerce, TX 75429-3011, USA

Received 3 May 2007; accepted 24 May 2007

Abstract—A new type of catalyst for the asymmetric Michael addition reaction has been designed and synthesized. This catalyst, (*S*)-pyrrolidine arenesulfonamide **1**, resulted in high yields (up to 93%), excellent diastereoselectivities (*syn/anti* ratio up to 99/1), and excellent enantioselectivities (ee up to 99%) for various cyclic ketones and nitroolefins.
© 2007 Elsevier Ltd. All rights reserved.

1. Introduction

The organocatalytic asymmetric Michael addition reaction has emerged as one of the most powerful and efficient methods for C–C bond formation in synthetic organic chemistry.¹ Several highly efficient chiral organocatalysts have been designed and synthesized for this reaction.² Proline and its pyrrolidine-type chiral amine derivatives are among the organocatalysts that have been found to be highly successful for asymmetric organic transformations.³ The pioneering works by Hanessian,^{3a} List,^{3b} and Enders^{3c} serve to demonstrate that L-proline is a very effective catalyst for asymmetric Michael addition reactions, the key step for these reactions being the formation of an enamine intermediate. Owing to the poor solubility of proline in many organic solvents, numerous novel proline derivatives, such as pyrrolidine-pyridine,⁴ aminomethylpyrrolidine,⁵ 2,2'-bipyrrolidine,⁶ pyrrolidineterazole,⁷ (*S*)-(+)-2-pyrrolidinemethanol,⁸ pyrrolidine-thiourea,⁹ and pyrrolidine-based chiral ionic liquids¹⁰ which have improved solubility, have been developed and used as excellent organocatalysts in asymmetric Michael addition reactions.

Recently, Wang et al.¹¹ described the synthesis of (*S*)-pyrrolidine trifluoromethanesulfonamide and hydrophobic polyfluorous pyrrolidine sulfonamide that effectively catalyzes diastereo- and enantioselective Michael addition reactions of ketones and aldehydes with nitroolefins. However, a relatively low enantioselectivity was obtained when nitrostyrene, which contained an electron-withdrawing CF₃


group, was used as a Michael acceptor. Although the catalysts developed to date exhibit a relatively high reactivity and selectivity, the development of new catalysts that are capable of improving diastereo- and enantioselectivity for the asymmetric Michael reaction at room temperature is still warranted.

2. Results and discussion

It has been proposed that the asymmetric Michael reaction catalyzed by proline proceeds via an enamine intermediate, and that both the secondary amine of the pyrrolidine ring and the carboxylic acid functionalities are required for the catalytic activity. Herein, we have designed a new type of proline-derived catalyst, (*S*)-pyrrolidine arenesulfonamide **1**, which has proven to be an effective organocatalyst for reactions where proline derivatives are normally used. The two electron-withdrawing trifluoromethyl groups on the phenyl ring, combined with sulfonyl group are expected to effectively increase the acidity of the sulfonamide hydrogen and as a result, facilitate required proton transfer. Catalyst **1** can be easily prepared from the commercially available *N*-Boc-(*S*)-2-aminomethylpyrrolidine and 3,5-bis(trifluoromethyl)benzenesulfonyl chloride, as shown in Scheme 1. Herein, we report the results of the studies using **1** as catalyst to promote highly diastereo- and enantioselective Michael addition reactions of ketones with nitroolefins.

Initially, the Michael reaction of cyclohexanone and nitrostyrene in various solvents was examined at room temperature using (*S*)-pyrrolidine arenesulfonamide **1** as the

* Corresponding author. E-mail: allan_headley@tamuc.edu



Scheme 1. Synthesis of (*S*)-pyrrolidine arenesulfonamide.

catalyst, the results are summarized in Table 1. Both CH₃CN and THF gave high diastereoselectivities, but yields were low (8–10%) (Table 1, entries 1 and 2). Dichloromethane and an ionic liquid [BMIM]BF₄ were also poor solvents in terms of product yields (Table 1, entries 4 and 5). DMSO, *i*-PrOH, and DMF were superior solvents and showed good yields, high enantioselectivities, and diastereoselectivities (Table 1, entries 6–8). Based on these results, *i*-PrOH was chosen as the solvent to study the effectiveness of catalyst **1**. The Michael addition reaction proceeded smoothly at room temperature to give the desired adduct **2a** in 83% yield with high enantioselectivity (94% ee) and diastereoselectivity (*syn/anti* = 98/2).

Table 1. Solvent effect for asymmetric Michael addition reaction of cyclohexanone and *trans*- β -nitrostyrene

Entry	Solvent	Yield ^a (%)	ee ^b (%)	dr (<i>syn/anti</i>) ^d
1	CH ₃ CN	10	c	96/4
2	THF	8	c	93/7
3	DCM	<5	c	c
4	Neat	8	c	c
5	[BMIM]BF ₄	5	c	c
6	DMSO	61	83	95/5
7	<i>i</i> -PrOH	83	94	98/2
8	DMF	85	92	92/8

^a Yield of isolated product.

^b Determined by chiral HPLC analysis (Chiralpak AS-H).

^c Not determined.

^d Determined by ¹H NMR spectroscopy (400 MHz).

Having established the standard reaction conditions for the Michael addition of cyclohexanone with *trans*- β -nitrostyrene, we next investigated the scope of the Michael reaction for which catalyst **1** is effective with a series of ketones and nitroolefins in *i*-PrOH as the solvent; the results were shown in Table 2. From these results, it is obvious that all cyclic ketones efficiently undergo Michael reactions with different aryl-substituted nitroolefins in the presence of 15 mol % of catalyst **1** in *i*-PrOH at room temperature to give the Michael adducts **2a–i** in high yields with excellent enantio- (92–99% ee) and diastereoselectivities (*syn/anti* ratio up to 99/1). The results in Table 1 also show that the nature of the substituents on aryl groups slightly influences the yields and enantioselectivities. For nitroolefins with electron-rich groups (methyl and methoxy), the reaction proceeded smoothly to afford Michael adduct **2b,c** in

Table 2. Asymmetric Michael reaction of cycloketones to nitroolefins

Entry	Product	Yield ^a (%)	ee ^b (%)	dr (<i>syn/anti</i>) ^c
1	2a	83	94	98/2
2	2b	77	99	96/4
3	2c	65	99	99/1
4	2d	87	95	99/1
5	2e	83	94	94/6
6	2f	91	93	99/1
7	2g	93	96	98/2
8	2h	92	95	99/1
9	2i	92	92	98/2
10	2j	90	93	91/9

^a Isolated yield.

^b Determined by Chiral HPLC.

^c Determined by ¹H NMR.

nearly enantiomerically pure form (99% ee) and with excellent diastereoselectivities, although the isolated yields were

relatively low (65–77%) (Table 2, entries 2 and 3). For nitroolefins with electron-withdrawing groups, the Michael adducts **2d–h** were obtained in high yields (83–93%) with excellent enantio- (93–96% ee) and diastereoselectivities (*syn/anti* ratio up to 99/1) (Table 2, entries 4–7). Moreover, tetrahydrothiopyran-4-one and tetrahydro-4*H*-pyran-4-one were also suitable substrates as Michael donors (Table 2, entries 8 and 9). Compared to the results obtained by Wang et al.^{11b} in which (*S*)-pyrrolidine trifluoromethanesulfonamide was used as the catalyst, the (*S*)-pyrrolidine arenesulfonamide **1** is superior in enantioselectivity for nitroolefins bearing electron-deficient aryl groups.¹²

3. Conclusion

In conclusion, a new catalyst, (*S*)-pyrrolidine arenesulfonamide **1**, was prepared and successfully applied to the asymmetric Michael addition reaction of cyclic ketones with nitroolefins. The reactions proceeded smoothly at room temperature to give high yields (up to 93%), excellent diastereoselectivities (*syn/anti* ratio up to 99/1), and excellent enantioselectivities (ee up to 99%). The design of improved catalysts and their application to other types of reactions are currently being investigated in our laboratory.

4. Experimental

4.1. (*S*)-2-[(2,6-Trifluoromethanebenzenesulfonyl)amino-methyl]pyrrolidine **1**

To a solution of *N*-Boc-(*S*)-2-aminomethylpyrrolidine (500 mg, 2.5 mmol) in CH₂Cl₂ (15 mL) was added Et₃N (0.42 mL, 3.0 mmol). The solution was cooled to 0 °C and 3,5-bis(trifluoromethyl)benzenesulfonyl chloride (782 mg, 2.5 mmol) was added. After the addition, the reaction mixture was brought to room temperature and stirred for 17 h, diluted in CH₂Cl₂ (60 mL) and washed with 1 M HCl (5 mL), saturated aqueous NaHCO₃ (10 mL), and brine (15 mL). The organic phase was dried over Na₂SO₄ and concentrated to give the residue, which was used for the next step without further purification.

The above compound was dissolved in a 1/1 mixture of trifluoroacetic acid and dichloromethane (10 mL) and the solution was stirred for 2 h at rt, at which time the solvent was evaporated under reduced pressure. The pH was adjusted to 8 with aqueous NaHCO₃ and the aqueous phase was extracted with CH₂Cl₂ (3 × 20 mL). The organic phase was dried over Na₂SO₄ and the solvent was evaporated to give the residue, which was recrystallized from ethyl acetate and hexane to give the pure title compound **1** (1.05 g, 88% for two steps). Mp: 189–191 °C; $[\alpha]_{\text{D}}^{20} = -10$ (*c* 0.30, MeOH); ¹H NMR (300 MHz, CD₃OD) δ 8.44 (s, 2H), 8.33 (s, 1H), 3.75–3.65 (m, 1H), 3.40–3.13 (m, 4H), 2.21–2.00 (m, 3H), 1.65–1.78 (m, 1H); ¹³C NMR (75 MHz, CD₃OD) δ 144.3, 134.1 (q, *J* = 137.2 Hz, 2C), 128.7, 125.5, 122.7; IR (neat) $\nu = 1687, 1352, 1278, 1129 \text{ cm}^{-1}$; HRMS (ESI) *m/z* (%) calcd for C₁₃H₁₅F₆N₂O₂S: 377.0753, found: 377.0752.

4.2. The data for the Michael addition reaction

4.2.1. (*S*)-2-((*R*)-2-Nitro-1-phenylethyl)cyclohexanone **2a**.⁴

Typical procedure: Catalyst **1** (11 mg, 15 mol %) was dissolved in *i*-PrOH (1 mL) and cyclohexanone (59 mg, 0.6 mmol) and β-nitrostyrene (30 mg, 0.2 mmol) was added. The reaction mixture stirred at room temperature for 4 days. The reaction mixture was concentrated in vacuum and the residue was purified by flash silica gel column (eluent: hexane/ethyl acetate = 4/1) to give the Michael adduct **2a** (41 mg, 83%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.35–7.23 (m, 3H), 7.20–7.14 (m, 2H), 4.94 (dd, *J* = 12.4 and 4.4 Hz, 1H), 6.43 (dd, *J* = 12.4 and 10.0 Hz, 1H), 3.76 (dt, *J* = 9.6 and 4.4 Hz, 1H), 2.74–2.64 (m, 1H), 2.52–2.34 (m, 2H), 2.13–2.03 (m, 1H), 1.83–1.50 (m, 4H), 1.30–1.18 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 211.9, 137.7, 128.9, 128.2, 127.8, 78.9, 52.5, 43.9, 42.7, 33.2, 28.5, 25.0; $[\alpha]_{\text{D}}^{20} = -23.2$ (*c* 0.15, CH₂Cl₂); *syn/anti* = 98/2; ee = 94%; HPLC (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 0.7 mL/min, λ = 238 nm): *t*_{minor} = 22.7 min, *t*_{major} = 35.2 min.

4.2.2. (*S*)-2-((*R*)-1-(4-Methylphenyl)-2-nitroethyl)cyclohexanone **2b**.^{11b}

¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, *J* = 8.0 Hz, 2H), 7.04 (d, *J* = 8.0 Hz, 2H), 4.91 (dd, *J* = 12.4 and 4.8 Hz, 1H), 4.62 (dd, *J* = 12.4 and 10.0 Hz, 1H), 3.72 (dt, *J* = 10.0 and 4.8 Hz, 1H), 2.71–2.62 (m, 1H), 2.51–2.32 (m, 2H), 2.31 (s, 3H), 2.12–2.02 (m, 1H), 1.82–1.50 (m, 4H), 1.30–1.18 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 212.0, 137.4, 134.6, 129.6, 128.0, 79.0, 52.6, 43.6, 42.7, 33.2, 28.5, 25.0, 21.0; $[\alpha]_{\text{D}}^{20} = -17.9$ (*c* 0.36, CH₂Cl₂); *syn/anti* = 96/4; ee = 99%; HPLC (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 0.8 mL/min, λ = 254 nm): *t*_{minor} = 15.4 min, *t*_{major} = 25.9 min.

4.2.3. (*S*)-2-((*R*)-1-(4-Methoxyphenyl)-2-nitroethyl)cyclohexanone **2c**.⁴

¹H NMR (400 MHz, CDCl₃) δ 7.08 (d, *J* = 8.8 Hz, 2H), 6.83 (d, *J* = 8.8 Hz, 2H), 4.95 (dd, *J* = 12.4 and 4.4 Hz, 1H), 4.58 (dd, *J* = 12.4 and 10.0 Hz, 1H), 3.78 (s, 3H), 3.72 (dt, *J* = 10.0 and 4.4 Hz, 1H), 2.69–2.60 (m, 1H), 2.53–2.33 (m, 2H), 2.13–2.04 (m, 1H), 1.82–1.50 (m, 4H), 1.30–1.17 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 212.0, 137.4, 134.6, 129.6, 128.0, 79.0, 52.6, 43.6, 42.7, 33.2, 28.5, 25.0, 21.0; $[\alpha]_{\text{D}}^{20} = -11.8$ (*c* 0.31, CH₂Cl₂); *syn/anti* = 99/1; ee = 99%. HPLC (Chiralpak AD, *i*-propanol/hexane = 10/90, flow rate 0.5 mL/min, λ = 254 nm): *t*_{minor} = 25.5 min, *t*_{major} = 31.8 min.

4.2.4. (*S*)-2-((*R*)-1-(2-Trifluoromethanophenyl)-2-nitroethyl)cyclohexanone **2d**.^{11b}

¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 7.6 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.39 (dd, *J* = 16.4 and 10.0 Hz, 2H), 5.02 (dd, *J* = 12.0 and 6.8 Hz, 1H), 4.76 (dd, *J* = 12.0 and 4.0 Hz, 1H), 4.13–4.05 (m, 1H), 3.06–2.96 (m, 1H), 2.54–2.40 (m, 3H), 2.18–2.08 (m, 1H), 1.84–1.52 (m, 4H), 1.38–1.24 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 211.5, 137.1, 132.4, 128.0, 127.8, 126.6 (q, *J* = 20.8 Hz, 1C), 125.5, 122.7, 78.5, 52.5, 43.0, 39.1, 33.5, 28.7, 25.5; $[\alpha]_{\text{D}}^{20} = -15.7$ (*c* 0.64, CH₂Cl₂); *syn/anti* = 99/1; ee = 95%; HPLC (Chiralpak AD, *i*-propanol/hexane = 10/90, flow rate 0.5 mL/min, λ = 254 nm): *t*_{minor} = 13.4 min, *t*_{major} = 18.3 min.

4.2.5. (S)-2-((R)-1-(4-Bromophenyl)-2-nitroethyl)cyclohexanone 2e.^{10a} ¹H NMR (400 MHz, CDCl₃) δ 7.45 (dd, *J* = 6.8 and 1.6 Hz, 2H), 7.06 (dd, *J* = 6.8 and 1.6 Hz, 2H), 4.92 (dd, *J* = 12.4 and 4.4 Hz, 1H), 4.60 (dd, *J* = 12.4 and 10.0 Hz, 1H), 3.74 (dt, *J* = 9.6 and 4.4 Hz, 1H), 2.70–2.60 (m, 1H), 2.52–2.32 (m, 2H), 2.14–2.04 (m, 1H), 1.84–1.52 (m, 4H), 1.30–1.18 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 211.4, 136.8, 132.1, 129.9, 121.7, 78.5, 52.3, 43.4, 42.7, 33.1, 28.4, 25.0; [α]_D²⁰ = -14.2 (*c* 0.40, CH₂Cl₂); *syn/anti* = 94/6; ee = 94%; HPLC (Chiralpak AS-H, *i*-propanol/hexane = 10/90, flow rate 1 mL/min, λ = 254 nm): *t*_{minor} = 18.2 min, *t*_{major} = 32.7 min.

4.2.6. (S)-2-((R)-2-Nitro-(2-nitrophenyl)ethyl)cyclohexanone 2f.⁹ ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, *J* = 8.0 Hz, 1H), 7.59 (t, *J* = 8.0 Hz, 1H), 7.48–7.42 (m, 2H), 4.98–4.87 (m, 2H), 4.32 (dt, *J* = 8.8 and 4.8 Hz, 1H), 2.99–2.91 (m, 1H), 2.52–2.32 (m, 2H), 2.16–2.08 (m, 1H), 1.88–1.78 (m, 2H), 1.72–1.40 (m, 4); ¹³C NMR (100 MHz, CDCl₃) δ 211.0, 150.8, 133.1, 132.8, 129.3, 128.6, 124.9, 77.6, 52.2, 42.8, 38.7, 33.2, 28.3, 25.3; [α]_D²⁰ = -148.3 (*c* 0.65, CH₂Cl₂); *syn/anti* = 99/1; ee = 93%; HPLC (Chiralpak AD, *i*-propanol/hexane = 5/95, flow rate 1 mL/min, λ = 238 nm): *t*_{minor} = 32.3 min, *t*_{major} = 48.0 min.

4.2.7. (S)-2-((R)-1-(2,4-Dichlorophenyl)-2-nitroethyl)cyclohexanone 2g.⁹ ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 2.0 Hz, 1H), 7.28–7.14 (m, 2H), 4.95–4.80 (m, 2H), 4.25 (dt, *J* = 9.6 and 4.8 Hz, 1H), 2.93–2.82 (m, 1H), 2.52–2.32 (m, 2H), 2.16–2.07 (m, 1H), 1.87–1.50 (m, 4H), 1.40–1.25 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 211.3, 135.2, 134.1, 130.1, 127.7, 51.6, 42.8, 40.6, 33.1, 28.4, 25.3; [α]_D²⁰ = -40.7 (*c* 0.71, CH₂Cl₂); *syn/anti* = 98/2; ee = 96%; HPLC (Chiralpak AS-H, *i*-propanol/hexane = 5/95, flow rate 1 mL/min, λ = 238 nm): *t*_{minor} = 16.0 min, *t*_{major} = 29.9 min.

4.2.8. (S)-2-((R)-1-(2-Chlorophenyl)-2-nitroethyl)cyclohexanone 2h.^{10a} ¹H NMR (400 MHz, CDCl₃) δ 7.37 (d, *J* = 6.8 Hz, 2H), 7.30–7.28 (m, 3H), 4.90 (d, *J* = 2.0 Hz, 1H), 4.89 (s, 1H), 4.35–4.25 (m, 1H), 2.98–2.86 (m, 1H), 2.52–2.34 (m, 2H), 2.16–2.06 (m, 1H), 1.86–1.54 (m, 4H), 1.40–1.24 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 211.6, 135.4, 134.5, 130.3, 129.4, 128.9, 127.3, 77.2, 51.7, 42.8, 41.0, 33.0, 28.5, 25.2; [α]_D²⁰ = -49.2 (*c* 0.50, CHCl₃); *syn/anti* = 99/1; ee = 95%; HPLC (Chiralpak AD, *i*-propanol/hexane = 5/95, flow rate 1 mL/min, λ = 254 nm): *t*_{minor} = 13.0 min, *t*_{major} = 18.9 min.

4.2.9. (R)-Tetrahydro-3-((R)-2-nitro-1-phenylethyl)pyran-4-one 2i.^{11b} ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.26 (m, 3H), 7.21–7.16 (m, 2H), 4.96 (dd, *J* = 12.4 and 4.8 Hz, 1H), 4.64 (dd, *J* = 12.4 and 10.0 Hz, 1H), 4.20–4.10 (m, 1H), 3.87–3.68 (m, 2H), 3.70 (dd, *J* = 11.2 and 5.2 Hz, 1H), 3.27 (dd, *J* = 11.2 and 10.0 Hz, 1H), 2.93–2.83 (m, 1H), 2.73–2.61 (m, 1H), 2.60–2.53 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 207.3, 136.2, 129.2, 128.3, 127.9, 78.7, 71.6, 69.0, 53.3, 42.9, 41.3; [α]_D²⁰ = -17.7 (*c* 0.44, CH₂Cl₂); *syn/anti* = 98/2; ee = 92%; HPLC (Chiralpak AS-H, *i*-propanol/hexane = 40/60, flow rate 0.5 mL/min, λ = 254 nm): *t*_{minor} = 22.3 min, *t*_{major} = 29.0 min.

4.2.10. (R)-Tetrahydro-3-((R)-2-nitro-1-phenylethyl)pyran-4-one 2j.^{11b} ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.26 (m, 3H), 7.21–7.16 (m, 2H), 4.96 (dd, *J* = 12.4 and 4.8 Hz, 1H), 4.64 (dd, *J* = 12.4 and 10.0 Hz, 1H), 4.20–4.10 (m, 1H), 3.87–3.68 (m, 2H), 3.70 (dd, *J* = 11.2 and 5.2 Hz, 1H), 3.27 (dd, *J* = 11.2 and 10.0 Hz, 1H), 2.93–2.83 (m, 1H), 2.73–2.61 (m, 1H), 2.60–2.53 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 207.3, 136.2, 129.2, 128.3, 127.9, 78.7, 71.6, 69.0, 53.3, 42.9, 41.3; [α]_D²⁰ = -27.9 (*c* 0.45, CH₂Cl₂); *syn/anti* = 91/9; ee = 93%; HPLC (Chiralpak AS-H, *i*-propanol/hexane = 50/50, flow rate 0.5 mL/min, λ = 254 nm): *t*_{minor} = 20.7 min, *t*_{major} = 25.8 min.

Acknowledgement

We are grateful to the Robert A. Welch Foundation (T-1460) for financial support of this research.

References

- Perlmutter, P. *Conjugate Addition Reactions in Organic Synthesis*; Pergamon: Oxford, 1992.
- For selected reviews regarding of organocatalysis, see: (a) List, B. *Acc. Chem. Res.* **2004**, *37*, 548; (b) Dalko, P. I.; Moisan, L. *Angew. Chem., Int. Ed.* **2004**, *43*, 5138; (c) Notz, W.; Tanaka, F.; Barbas, C. F., III. *Acc. Chem. Res.* **2004**, *37*, 580; (d) Seayad, J.; List, B. *Org. Biomol. Chem.* **2005**, *3*, 719; (e) Duthaler, R. O. *Angew. Chem., Int. Ed.* **2003**, *42*, 975.
- (a) Hanessian, S.; Pham, V. *Org. Lett.* **2000**, *2*, 2975; (b) List, B.; Pojarliev, P.; Martin, H. J. *Org. Lett.* **2001**, *3*, 2423; (c) Enders, D.; Seki, A. *Synlett* **2002**, 26; (d) Chi, Y.; Gellman, S. H. *Org. Lett.* **2005**, *7*, 4253; (e) Mosse, S.; Alexakis, A. *Org. Lett.* **2005**, *7*, 4361; (f) Cobb, A. J. A.; Shaw, D. M.; Longbottom, D. A.; Gold, J. B.; Ley, S. V. *Org. Biomol. Chem.* **2005**, *3*, 84; (g) Mitchell, C. E. T.; Cobb, A. J. A.; Ley, S. V. *Synlett* **2005**, 611; (h) Mase, N.; Thayumanavan, R.; Tanaka, F.; Barbas, C. F., III. *Org. Lett.* **2004**, *6*, 2527; (i) Planas, L.; Perand-Viret, J.; Royer, J. *Tetrahedron: Asymmetry* **2004**, *15*, 2399; (j) Cobb, A. J. A.; Longbottom, D. A.; Shaw, D. M.; Ley, S. V. *Chem. Commun.* **2004**, 1808; (k) Betancort, J. M.; Sakthivel, K.; Thayumanavan, R.; Barbas, C. F., III. *Tetrahedron Lett.* **2001**, *42*, 4441; (l) Betancort, J. M.; Barbas, C. F., III. *Org. Lett.* **2001**, *3*, 3737.
- Ishii, T.; Fujioka, S.; Sekiguchi, Y.; Kotsuki, H. *J. Am. Chem. Soc.* **2004**, *126*, 9558.
- (a) Mase, N.; Thayumanavan, R.; Tanaka, F.; Barbas, C. F., III. *Org. Lett.* **2004**, *6*, 2527; (b) Betancort, J. M.; Sakthivel, K.; Thayumanavan, R.; Tanaka, F.; Barbas, C. F., III. *Synthesis* **2004**, 1509.
- (a) Alexakis, A.; Andrey, O. *Org. Lett.* **2002**, *4*, 3611; (b) Andrey, O.; Vidonne, A.; Alexakis, A. *Tetrahedron Lett.* **2003**, *44*, 7901; (c) Andrey, O.; Alexakis, A.; Bernardinelli, G. *Org. Lett.* **2003**, *5*, 2559; (d) Andrey, O.; Alexakis, A.; Tomassini, A.; Bernardinelli, G. *Adv. Synth. Catal.* **2004**, *346*, 1147.
- (a) Cobb, A. J. A.; Longbottom, D. A.; Shaw, D. M.; Ley, S. V. *Chem. Commun.* **2004**, 1808; (b) Cobb, A. J. A.; Shaw, D. M.; Longbottom, D. A.; Gold, J. B.; Ley, S. V. *Org. Biomol. Chem.* **2005**, *3*, 84.
- Reyes, E.; Vicario, J. L.; Badia, D.; Carrillo, L. *Org. Lett.* **2006**, *8*, 6135.
- Cao, C.-L.; Ye, M.-C.; Sun, X.-L.; Tang, Y. *Org. Lett.* **2006**, *8*, 2901.

10. (a) Luo, S.-Z.; Mi, X.; Zhang, L.; Liu, S.; Xu, H.; Cheng, J.-P. *Angew. Chem., Int. Ed.* **2006**, *45*, 3093; (b) Ni, B.; Zhang, Q.; Headley, A. D. *Green Chem.* **2007**, *9*. doi:10.1039/b702081c.
11. (a) Wang, W.; Wang, J.; Li, H. *Angew. Chem., Int. Ed.* **2005**, *44*, 1369; (b) Wang, J.; Li, H.; Lou, B.; Zu, L.; Guo, H.; Wang, W. *Chem. Eur. J.* **2006**, *12*, 4321; (c) Zu, L.; Wang, J.; Li, H.; Wang, W. *Org. Lett.* **2006**, *8*, 3077.
12. The (*S*)-pyrrolidine trifluoromethanesulfonamide (20 mol %) catalyzed Michael addition of *trans*- β -nitro-2-(trifluoromethyl)styrene with cyclohexanone at 0 °C resulted in 70% yield and 88% ee (see Ref. 11b).